Table 1.
all of the ncRNAs associated with chemotherapeutic resistance in BCa
| Study | Year | Gene | Country | Drug | Results |
|---|---|---|---|---|---|
| Chen [17] | 2020 | MST1P2, miR-133b | China | Cisplatin | MST1P2/miR-133b axis had an important role in cisplatin-resistance of bladder cancer through SIRT1/p53 pathway. |
| Chen [18] | 2019 | HIF1A-AS2 | China | Cisplatin | HIF1A-AS2 enhances survival of tumor cells by upregulating HMGA1. |
| Wu [19] | 2019 | UCA1 | China | Rapamycin | UCA1 acts as an endogenous sponge to down regulate the miR-582-5p which resulted in ATG7 over expression. |
| Zhang [20] | 2017 | GAS5 | China | Doxorubicin | GAS5 increased doxorubicin-induced apoptosis through BCL-2 suppression. |
| Liu [21] | 2019 | MALAT1 | China | Cisplatin | MALAT1 induced chemo resistance through regulating miR-101-3p/VEGFC axis. |
| Li [22] | 2019 | GHET1 | China | Gemcitabine | GHET1 up regulated the MRP1. |
| An [23] | 2018 | FOXD2-AS1 | China | Gemcitabine | FOXD2-AS1 indirectly targets the ABCC3 through miR-143 sponging. |
| Wang [24] | 2017 | MiR-143 | China | Gemcitabine | The miR-143 attenuated gemcitabine resistance via IGF-1R suppression. |
| Fan [25] | 2014 | UCA1 | China | Cisplatin | UCA1 overexpression was contributed to upregulation of WNT6. |
| Pan [26] | 2016 | UCA1 | China | Cisplatin, Gemcitabine | UCA1 activates miR-196a-5p via CREB which results in gemcitabine/cisplatin resistance. |
| Xie [27] | 2017 | TUG1 | China | Doxorubicin | TUG1 knockdown decreased Dox resistance through restraining the activity of Wnt/β-catenin pathway. |
| Xie [28] | 2018 | CDKN2B-AS | China | Gemcitabine | CDKN2B-AS induced Gemcitabine-resistance via sponging Let-7. |
| Zhuang [29] | 2017 | LET | China | Gemcitabine | TGFβ1 promotes gemcitabine resistance through LncRNA-LET/NF90/miR-145 axis. |
| Li [30] | 2019 | DLEU1 | China | Cisplatin | DLEU1 up regulated the HS3ST3B1 via miR-99b suppression. |
| Zhao [31] | 2019 | NEAT1.1 | China | Cisplatin | NEAT1.1 was down regulated following cisplatin treatment. |
| Xiao [32] | 2018 | MiR-22-3p | China | Paclitaxel, Adriamycin, Epirubicin, hydroxycamptothecin, Cisplatin, and Gemcitabine | MiR-22-3p enhanced resistance to chemotherapy in bladder tumor cells through suppressing NET1. |
| Deng [33] | 2015 | MiR-27a | China | Paclitaxel, Adriamycin, Cisplatin | MiR-27a/RUNX-1 pathway has a key function in chemo-resistance. |
| Drayton [34] | 2014 | MiR-27a | UK | Cisplatin | MiR-27a deregulation induced cisplatin resistance in bladder cancer cells via up regulating SLC7A11. |
| Bu [35] | 2014 | MiR-101 | China | Cisplatin | MiR-101 regulates cisplatin sensitivity in bladder tumor cell lines via targeting the COX-2. |
| Vinall [36] | 2012 | MiR-34a | USA | Cisplatin | MiR-34a sensitized tumor cells to cisplatin by targeting SIRT-1 and CDK6. |
| Li [37] | 2014 | MiR-34a | China | Cisplatin | MiR-34a targets CD44 after cisplatin therapy. |
| Liu [38] | 2018 | MiR-34a | China | Epirubicin | MiR-34a significantly reduced Epirubicin chemo resistance in bladder tumor cells through targeting TCF1 and LEF1. |
| Zhang [39] | 2017 | MiR-34a | China | Cisplatin, Gemcitabine | MiR34a regulation of GOLPH3 is active in bladder CSCs resistant to gemcitabine and cisplatin. |
| Tan [40] | 2019 | MiR-34b-3p | China | Paclitaxel, Adriamycin, Epirubicin, Cisplatin, Pirarubicin | MiR-34b-3p attenuated chemo resistance in bladder cancer through suppressing CCND2 and P2RY1. |
| Luan [41] | 2018 | MiR-98 | China | Cisplatin, Doxorubicin | MiR-98 promotes chemo-resistance through targeting LASS2. |
| Li [42] | 2019 | MiR-101-3p | China | Cisplatin | MiR-101-3p decreased cisplatin-resistance in bladder urothelial carcinoma through repressing EZH2 and MRP1. |
| Cao [43] | 2018 | MiR-129-5p | China | Gemcitabine | MiR-129-5p inhibits resistance to gemcitabine in bladder cancer cells and promotes their apoptosis via targeting WNT5a. |
| Lv [44] | 2015 | MiR-193a-3p | China |
Pirarubicin, Paclitaxel, Adriamycin, Epirubicin Hydrochloride, and Cisplatin |
MiR-193a-3p mediated HOXC9 down regulation which resulted in poorer sensitivity to chemotherapeutic drugs. |
| Deng [45] | 2015 | MiR-193a-3p | China | Pirarubicin, Paclitaxel, Adriamycin, Epirubicin hydrochloride, and Cisplatin | PSEN1 was directly targeted by miR-193a-3p and executed its impact on the multi-chemo resistance. |
| Lin [46] | 2017 | MiR-193b-3p | Taiwan | Cisplatin | CEBPD/miR-193b-3p axis had key roles in cisplatin response. |
| Deng [47] | 2014 | MiR-193a-3p | China | Paclitaxel, Adriamycin, Epirubicin Hydrochloride, and Cisplatin | MiR-193a-3p induced multi-drug resistance in bladder cancer cells through down regulating LOXL4. |
| Lv [48] | 2014 | MiR-193a-3p | China | Pirarubicin hydrochloride, Paclitaxel, Adriamycin, and Epirubicin hydrochloride | HIC2, SRSF2, and PLAU achieve their role in relaying miR-193a-3p’s effect on chemo resistance in bladder cancer through regulation of Myc/Max, NF-jB, DNA damage response, and NOTCH pathway. |
| Shindo [49] | 2018 | MiR-200b | Japan | Cisplatin | TNFSF10, ICAM1, and IGFBP3 were induced in the resistant cells as a result of miR-200b + cisplatin treatment. |
| Zhang [50] | 2015 | MiR-203 | China | Cisplatin | The miR-203 up regulation increased the cytotoxic effects of cisplatin and decreased tumor cell viability through suppressing Survivin and BCL-w. |
| Liu [51] | 2018 | MiR-214 | China | Cisplatin | MiR-214 decreased chemo resistance in bladder cancer tissues and cell lines by suppressing NTN1. |
| Li [52] | 2017 | MiR-218 | China | Cisplatin | MiR-218 up regulation reduced cisplatin resistance through GLUT1 targeting. |
| Zeng [53] | 2016 | MiR-222 | China | Cisplatin | MiR-222 up regulation decreased cisplatin-induced apoptosis in bladder tumor cells through modulation of PPP2R2A/Akt/mTOR pathway. |